Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma

@inproceedings{Pachmann2011EfficacyCO,
  title={Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma},
  author={Katharina Pachmann and Oumar Camara and T. Kroll and M. Gajda and A. K. Gellner and Jana Wotschadlo and Ingo B. Runnebaum},
  booktitle={Journal of Cancer Research and Clinical Oncology},
  year={2011}
}
  • Katharina Pachmann, Oumar Camara, +4 authors Ingo B. Runnebaum
  • Published in
    Journal of Cancer Research…
    2011
  • Medicine
  • PurposeThe majority of targeted personalized cancer therapies are effective only in part of the patients, and most of these drugs are excessively expensive. Therefore, methods are urgently required, which reveal already early during treatment, whether the therapy is effective. In the present report, monitoring of circulating epithelial tumor cells (CETC) was used as a timely control of trastuzumab therapy in patients with HER2/neu-positive breast cancer.MethodsSeventy-nine sequential HER2/neu… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 21 CITATIONS

    liqDB: a small-RNAseq knowledge discovery database for liquid biopsy studies

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 33 REFERENCES

    Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.

    VIEW 3 EXCERPTS
    HIGHLY INFLUENTIAL

    The marriage of growth factor inhibitors and chemotherapy: bliss or bust?

    VIEW 3 EXCERPTS